Retatrutide Recherche – Pureté 99%+

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and verified to >99% HPLC purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same source, same purity specification — scaled to whatever your research needs.

GLP1-RC-RT Certificate of Analysis

GLP1-RC-RT material is analysed by an independent laboratory, and the resulting Certificate of Analysis is published online. A certificate reports what was measured in the sample submitted; vials are not batch-marked, so it is not matched to a particular vial or order.

New-U GLP1-RC-RT certificate evidence

Catalogue identifier: GLP1-RC-RT

Independent testing laboratory, report number and test date

Measured purity for the sample analysed

Certificate of Analysis at /coa/retatrutide; the method and any identity result are stated on the report

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-RT research material.

Domaines de recherche publiés

Les études publiées examinent l’activité des récepteurs, la pharmacocinétique et des critères métaboliques, hépatiques et glycémiques définis par protocole. Les résumés ci-dessous rapportent ce que les chercheurs ont mesuré dans ces études externes et ne constituent pas des instructions d’utilisation du matériel de recherche fourni ici.

Pharmacologie des récepteurs

Activité agoniste GLP-1R / GIPR / GCGR, caractérisée dans des études in-vitro publiées sur les récepteurs.

Critères métaboliques

Variation de la masse corporelle par rapport à la valeur initiale définie par protocole, mesurée dans la recherche clinique randomisée.

Critères hépatiques

Fraction de graisse hépatique par MRI-PDFF, mesurée dans une sous-étude randomisée de Phase 2a.

Critères glycémiques

HbA1c et critères liés au glucose, rapportés dans des recherches cliniques définies par protocole.

Pharmacocinétique

Exposition systémique et semivie apparente d'élimination, d'après une caractérisation pharmacocinétique publiée.

Scientific Overview

In short: GLP1-RC-RT est un composé de recherche triple agoniste GLP-1R / GIPR / GCGR, couramment appelé « Reta » dans les communautés de recherche.

Key research facts

Pharmacologie des récepteurs : activité agoniste caractérisée sur GLP-1R, GIPR et GCGR dans des études in-vitro publiées

Puissance GIPR rapportée comme 8.9 fois celle de GIP natif dans des études de pharmacologie des récepteurs

Modification C20 fatty-diacid avec liaison à l’albumine étudiée comme facteur contribuant à une exposition systémique prolongée

RCT de Phase 2 sur l’obésité (NEJM 2023, PMID 37385275) : les chercheurs ont rapporté une variation moyenne du poids corporel de −24.2% par rapport à la valeur initiale à la semaine 48 (bras 12 mg)

Phase 3 TRIUMPH-1 (NCT05929066 ; données principales rapportées par le sponsor, ADA 2026 ; pas encore évaluées par les pairs) : les chercheurs ont rapporté une variation moyenne du poids corporel de −28.3% par rapport à la valeur initiale à la semaine 80 (bras 12 mg)

These points summarise lab themes, not human outcomes.

Les travaux publiés caractérisent la pharmacologie des récepteurs, les modifications structurelles et le profil pharmacocinétique de cette classe de composés, parallèlement à des critères définis par protocole étudiés dans la recherche préclinique et clinique enregistrée.

La vérification des lots New-U et la littérature externe constituent deux ensembles de preuves distincts : les analyses de lot établissent l’identité analytique et la pureté du matériau testé ; les études publiées décrivent leurs propres matériaux et protocoles expérimentaux.

Architecture moléculaire

Retatrutide (LY3437943) est un peptide de 39 acides aminés conçu, d'un poids moléculaire de 4,894.6 Da, caractérisé dans des études de pharmacologie des récepteurs comme agoniste de trois récepteurs : GLP-1, GIP et glucagon. Ce profil à trois récepteurs est désigné dans la littérature comme un tri-agoniste "GGG".

Pharmacologie des récepteurs

Les valeurs EC50 rapportées sont de 0.775 nM sur GLP-1R, 0.0643 nM sur GIPR et 5.79 nM sur GCGR, avec une puissance GIPR rapportée comme 8.9 fois celle de GIP natif. Par rapport à la classe double GLP-1/GIP, le bras supplémentaire étudié est l’agonisme du glucagon receptor ; les travaux publiés examinent les critères de dépense énergétique hépatique associés à ce bras parallèlement aux critères incrétines mesurés pour la classe dans son ensemble. Tableau complet des voies : Mechanism of Action ci-dessous.

Modifications structurelles

Le backbone dérivé de GIP comporte des substitutions Aib2 et Aib20 étudiées pour la résistance à DPP-IV et α-methylleucine en position 13 étudiée pour la stabilité vis-à-vis des protéases. Un C20 fatty diacid lié à Lys17 via un espaceur AEEA-γGlu est étudié comme facteur de liaison à l'albumine contribuant à une exposition systémique prolongée.

Pharmacocinétique publiée

La demi-vie apparente d’élimination est rapportée à environ 6 jours selon les protocoles étudiés, avec un métabolisme protéolytique hépatique et aucune interaction médiée par CYP rapportée. Profil pharmacocinétique complet : Pharmacokinetics ci-dessous.

Recherche préclinique et clinique

Les résultats publiés résumés sur cette page concernent des études expérimentales et cliniques externes et leurs matériels et protocoles expérimentaux respectifs. Ils n’établissent pas la sécurité, l’efficacité ou l’équivalence clinique du matériel New-U GLP1-RC-RT. Résultats essai par essai : Research Observed Effects and Evidence Tier ci-dessous.

Références principales

Les publications évaluées par les pairs et le dossier d’essai clinique enregistré pour Retatrutide sont listés intégralement, avec les identifiants DOI/PMID/NCT, dans Source References ci-dessous.

At a glance

Mechanism and receptors Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for proteolytic stability and prolonged systemic exposure.

Molecular characteristics Molecular weight 4,894.6 Da.

Pharmacokinetics Half-life: Apparent elimination half-life reported at approximately 6 days under the investigated protocols; steady-state exposure reported after 3–4 weeks.

Evidence maturity Tier 1: Human clinical — The evidence tier describes the published literature on Retatrutide, the scientific subject. Retatrutide remains investigational and is not approved in any jurisdiction.

Analytical verification Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Research limitations Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-RT research material.

Receptor Pharmacology

Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for proteolytic stability and prolonged systemic exposure.

Pathway Effect Why it matters GLP-1R Agonist activity characterised in receptor pharmacology studies Reported EC50 0.775 nM; the receptor shared with the single- and dual-agonist reference compounds GIPR Agonist activity characterised experimentally Reported EC50 0.0643 nM; potency reported as 8.9-fold that of native GIP GCGR Agonist activity characterised experimentally Reported EC50 5.79 nM; the arm that distinguishes the triple agonist from dual GLP-1/GIP compounds in the literature Albumin-binding modification C20 fatty diacid via an AEEA-γGlu spacer Investigated as a contributor to prolonged systemic exposure (~6-day apparent half-life) Proteolytic stability Aib2, Aib20 and α-methylleucine-13 substitutions Structural modifications investigated for altered peptide stability against DPP-IV and protease cleavage

Deeper dive for scientific readers

Jastreboff et al. (N Engl J Med, 2023; PMID 37385275, DOI 10.1056/NEJMoa2301972) published the randomised Phase 2 obesity data: in the 12 mg arm investigators reported a mean change from baseline in body weight of −24.2% at week 48, with more than 90% of participants in that arm reaching a ≥10% reduction. Sanyal et al. (Nat Med, 2024; DOI 10.1038/s41591-024-03018-2) reported relative reductions in hepatic fat fraction of up to 82.4% in a Phase 2a MASLD population. The Phase 3 TRIUMPH-1 trial (NCT05929066) reported a mean change from baseline in body weight of −28.3% at week 80 in the 12 mg arm, with 45.3% of that arm reaching a ≥30% reduction — sponsor-reported topline, ADA 2026; not yet peer-reviewed. Published pharmacokinetic work reports hepatic proteolytic metabolism without CYP involvement and steady-state exposure after 3–4 weeks of the protocol-defined weekly administration. Every figure here is an observation recorded in the cited external study of the investigational compound.

Common Questions People Are Asking

Qu'est-ce que GLP1-RC-RT ?

GLP1-RC-RT est la désignation de catalogue New-U pour ce composé de recherche vérifié analytiquement, couramment appelé « Reta » dans les communautés de recherche. Il est fourni comme matériel de recherche en laboratoire : ce n’est pas un médicament, un traitement, un générique pharmaceutique ou un produit thérapeutique ; il n’est équivalent à aucun produit clinique ou commercial et n’est pas proposé pour un usage humain ou vétérinaire.

Quels systèmes de récepteurs ont été étudiés ?

La pharmacologie in-vitro publiée caractérise l’activité agoniste sur trois récepteurs : GLP-1R (EC50 rapporté 0.775 nM), GIPR (EC50 rapporté 0.0643 nM, avec une puissance rapportée comme 8.9 fois celle de GIP natif) et GCGR (EC50 rapporté 5.79 nM). Les travaux structurels étudient également la modification C20 fatty-diacid de liaison à l’albumine comme facteur contribuant à une exposition systémique prolongée, ainsi que les substitutions Aib/α-methylleucine pour une stabilité protéolytique modifiée.

Quels tests analytiques accompagnent GLP1-RC-RT ?

The published GLP1-RC-RT Certificate of Analysis comes from an independent analytical laboratory and records the independent laboratory, report number, measured purity and test date for the sample analysed; the method and any identity result are stated on the report itself. Vials are not batch-marked, so a certificate describes the sample tested rather than a particular vial or order. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current Certificate of Analysis for GLP1-RC-RT?

The current certificate — laboratory, report number, measured purity and test date — is published at /coa/retatrutide, together with the testing history for the compound. It is readable before ordering rather than on request afterwards.

Que signifie une pureté HPLC >99% ?

Il s’agit d’une valeur de pureté obtenue par reversed-phase high-performance liquid chromatography avec normalisation de l’aire : le pic cible représente plus de 99% de l’aire intégrée totale des pics du chromatogramme pour l’échantillon testé. Cette valeur décrit uniquement la pureté chimique de cet échantillon. Elle ne décrit pas la stérilité, la teneur en endotoxines, la teneur en métaux lourds, l’équivalence pharmaceutique ou toute propriété clinique.

Quels essais cliniques sont référencés sur cette page ?

Trois études externes sur le composé expérimental : l'essai randomisé Phase 2 sur l'obésité (Jastreboff et al., N Engl J Med 2023; PMID 37385275, DOI 10.1056/NEJMoa2301972), l'essai Phase 2a MASLD (Sanyal et al., Nat Med 2024; DOI 10.1038/s41591-024-03018-2) et l'essai Phase 3 TRIUMPH-1 (ClinicalTrials.gov NCT05929066). Chaque résultat rapporté sur cette page est attribué à son étude, son bras et son point temporel. Les chiffres de TRIUMPH-1 sont des résultats principaux rapportés par le promoteur, présentés à ADA 2026 et pas encore évalués par les pairs; les chiffres de Phase 2 et Phase 2a proviennent de publications de revues évaluées par les pairs.

Comment la recherche clinique publiée est-elle distinguée des analyses de lots New-U ?

They are separate bodies of evidence and this page keeps them apart. Published clinical research is external work on Retatrutide as an investigational compound, using those studies' own materials and protocols; it establishes nothing about the material supplied here. New-U certificate testing is analytical work on a submitted sample of the GLP1-RC-RT material: the published report states the measured result for the sample analysed, and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-RT.

Sous quelle forme GLP1-RC-RT est-il fourni ?

GLP1-RC-RT is supplied as a lyophilised powder in sealed vials, in single-vial laboratory samples and sealed 10-vial research packs across the listed strengths; the Certificate of Analysis is published on the product page.

Comment le matériel de recherche en laboratoire doit-il être conservé ?

Conserver la poudre lyophilisée dans un congélateur à −20 °C. Si un protocole de laboratoire exige le matériel en solution, maintenir la solution obtenue au réfrigérateur à 1–6 °C, à l'abri de la lumière, et éviter les cycles répétés de congélation-décongélation, qui peuvent dégrader la modification fatty-acid. Les conditions de stockage constituent uniquement des informations de manipulation en laboratoire.

En quoi ce profil de récepteurs diffère-t-il des agonistes doubles et simples ?

Les trois classes se distinguent par la couverture des récepteurs : la littérature sur semaglutide décrit l'agonisme GLP-1R, celle sur tirzepatide décrit l'agonisme GIPR/GLP-1R, et ce composé est étudié pour l'agonisme GLP-1R/GIPR/GCGR. Leurs programmes cliniques ont été menés séparément, de sorte que les résultats publiés d'un programme ne constituent pas des comparaisons directes avec un autre.

GLP1-RC-RT est-il un médicament approuvé ?

Non. Le composé associé est expérimental et fait l’objet d’études cliniques enregistrées ; il n’est approuvé dans aucune juridiction. Le matériel fourni ici est du matériel de recherche en laboratoire et n’est pas proposé comme médicament, produit thérapeutique ou matériel destiné à l’usage humain ou vétérinaire.

Is it legal to buy Retatrutide?

In the United States, Retatrutide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 6 days under the investigated protocols; steady-state exposure reported after 3–4 weeks Absorption route Study protocols used subcutaneous administration; reported Tmax 12–72 h with dose-proportional (linear) exposure Bioavailability High subcutaneous exposure with dose-proportional plasma levels reported Metabolism / clearance Hepatic proteolytic metabolism plus β-oxidation of the C20 fatty-diacid chain reported; no CYP-mediated interactions reported Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes The C20 fatty-diacid/albumin interaction is the protraction mechanism described in the published pharmacokinetic literature. These are pharmacokinetic observations from external studies of the investigational compound, not a handling or administration instruction for research material.

Research-Observed Effects

Phase 3 TRIUMPH-1 (NCT05929066), obesity/overweight population, 12 mg arm: investigators reported a mean change from baseline in body weight of −28.3% at week 80; 45.3% of that arm reached ≥30% reduction (sponsor-reported topline, ADA 2026; not yet peer-reviewed)

Phase 2 obesity RCT (Jastreboff et al., NEJM 2023; PMID 37385275), 12 mg arm: investigators reported a mean change from baseline in body weight of −24.2% at week 48, with >90% of that arm reaching ≥10% reduction

Phase 2a MASLD trial (Sanyal et al., Nat Med 2024): investigators reported relative hepatic fat-fraction reductions of up to 82.4% at the protocol-defined timepoint, with steatosis resolution reported in >90% of the 12 mg arm

Type 2 diabetes studies: investigators reported HbA1c reductions of 1.3–2.0% as a protocol-defined endpoint in the investigated arms

Experimental pharmacology: glucagon-receptor agonism is investigated in the literature as a contributor to hepatic energy-expenditure endpoints measured alongside the incretin endpoints

Published Research Context

Registered clinical research of the investigational compound used protocol-defined intervention arms. The Phase 2 programme included 1 mg, 4 mg, 8 mg and 12 mg arms; the Phase 3 TRIUMPH-1 trial randomised 4 mg, 9 mg and 12 mg arms against placebo. Study protocols used once-weekly subcutaneous administration with a protocol-defined step-up period of roughly 20–24 weeks before the maintenance arm level was reached.

These figures are characteristics of external clinical trials. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the investigational compound. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Decreased appetite recorded as a reported adverse event

Rare

Discontinuation due to adverse events, reported by arm in TRIUMPH-1: 4.1% (4 mg), 6.9% (9 mg), 11.3% (12 mg) vs 4.9% placebo

Transient increase in resting heart rate

Transient glucose elevation attributed to the glucagon-receptor arm, monitored under the study protocols

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

Higher arm levels were reported with both larger endpoint changes and a higher adverse-event discontinuation rate

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Retatrutide, the scientific subject. Retatrutide remains investigational and is not approved in any jurisdiction. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-RT research material.

Tier 1 · Human clinical

TRIUMPH-1 pivotal Phase 3 obesity RCT — −28.3% mean change from baseline in body weight at week 80 (NCT05929066; sponsor-reported topline, ADA 2026; not yet peer-reviewed)

Triple-agonist Phase 2 obesity RCT — −24.2% mean change from baseline at week 48 (NEJM 2023; PMID 37385275)

Phase 2a MASLD trial — up to 82.4% relative hepatic fat-fraction reduction (Nat Med 2024)

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. · 2023 · PMID: 37385275 · DOI: 10.1056/NEJMoa2301972

Sanyal AJ et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. Nat Med. · 2024 · DOI: 10.1038/s41591-024-03018-2

TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight - Phase 3 (Pivotal). ClinicalTrials.gov trial registration record. · 2023

Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Sponsor announcement (topline; not peer-reviewed), presented at ADA 86th Scientific Sessions. · 2026

Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide - A Game Changer in Obesity Pharmacotherapy. Biomolecules (review). · 2025 · PMID: 40563436 · DOI: 10.3390/biom15060796

PubMed: peer-reviewed literature on Retatrutide

ClinicalTrials.gov: registered studies on Retatrutide

Retatrutide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

Engineered 39-amino-acid peptide (LY3437943)

Agonist activity characterised at GLP-1R, GIPR and GCGR in receptor-pharmacology studies

GIPR potency reported as 8.9-fold that of native GIP

C20 fatty-diacid albumin-binding modification investigated for prolonged systemic exposure

Apparent elimination half-life reported at approximately 6 days in published pharmacokinetic research

GLP1-RC-RT laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not an approved medicine

Specifications

Identifiant de catalogue New-U GLP1-RC-RT Sujet scientifique Retatrutide (LY3437943) Formule moléculaire Lipopeptide complexe (conjugué C20 diacid) Masse moléculaire 4894.6 Da Récepteurs caractérisés GLP-1R (EC50 0.775 nM), GIPR (EC50 0.064 nM), GCGR (EC50 5.79 nM) Pureté (analytique) >99% par normalisation de l’aire RP-HPLC Identité (analytique) Stated on the published Certificate of Analysis where the report includes an identity test Forme Poudre lyophilisée Demi-vie publiée Environ 6 jours (recherche pharmacocinétique externe) Conservation Lyophilisé : congélateur à −20 °C. Reconstitué : 1-6 °C, à l'abri de la lumière. Utilisation prévue Laboratory research material. Not for human or veterinary use.

Retatrutide Research — GLP1-RC-RT Laboratory Research Material

Retatrutide (LY3437943) is investigated in the literature as the triple-receptor entrant in the incretin class. First-generation compounds such as semaglutide are characterised as GLP-1R agonists; dual compounds such as tirzepatide are characterised as GIPR/GLP-1R agonists; retatrutide adds glucagon-receptor agonism, which is why it is described as a "GGG" tri-agonist.

Published clinical research reports protocol-defined endpoints: a mean change from baseline in body weight of −24.2% at week 48 in the Phase 2 12 mg arm (NEJM 2023), −28.3% at week 80 in the Phase 3 TRIUMPH-1 12 mg arm (sponsor-reported topline, ADA 2026; not yet peer-reviewed), and relative hepatic fat-fraction reductions of up to 82.4% in a Phase 2a MASLD population (Nat Med 2024). Each of those figures belongs to the study that produced it, in the population and at the timepoint that study defined.

New-U Research Compounds supplies GLP1-RC-RT as lyophilised, analytically verified laboratory research material; its published independent Certificate of Analysis records the independent laboratory, report number, measured purity and test date for the sample analysed. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-RT research material. GLP1-RC-RT is not an approved medicine and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

Gastric inhibitory polypeptide - Wikipedia

Glucagon - Wikipedia

Customer Reviews

Dobre śledzenie

Mogłem sam sprawdzać, gdzie jest przesyłka. Nie trzeba było dopytywać o każdy etap.

- Piotr Ś***** · 22 October 2026

Better checkout

I've used websites where the basket is a nightmare. This one was much easier to follow.

- aisha C***** · 20 October 2026

Comandă fără probleme - Retatrutide

Am găsit repede Retatrutide și am putut finaliza comanda fără bătăi de cap.

- Ramona M***** · 19 October 2026

More in Metabolic Research

Metabolic Research Semaglutide Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Semaglutide →

Metabolic Research Tirzepatide Tirzepatide is a dual GIP / GLP-1 receptor agonist characterised in published research, with imbalanced agonism favouring GIPR. GLP1-RC-TZ is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Tirzepatide →

Metabolic Research Cagrilintide Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology. Eloralintide →

Metabolic Research Liraglutide Liraglutide is a GLP-1 receptor agonist: a 31-residue analogue of GLP-1(7-37) with an Arg34 substitution and a C16 palmitoyl-γ-glutamate side chain on Lys26 that promotes albumin binding. Liraglutide →

Retatrutide vs related Metabolic Research compounds

Compound Price Purity spec COA Retatrutide from $160 >99% HPLC 4 published batches Semaglutide from $106 >99% HPLC 1 published batch Tirzepatide from $168 >99% HPLC 2 published batches

Retatrutide vs Semaglutide - full comparison

Retatrutide vs Tirzepatide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Retatrutide

Metabolic Research research compounds

Retatrutide research guide

Retatrutide pricing and packs

Research this compound

Research guide Retatrutide research guide Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for… Read the guide →

Compare Compare Retatrutide and Liraglutide Retatrutide vs Liraglutide: mechanism, receptor profile and specifications side by side. Compare →

Analytical evidence View the Retatrutide COA Latest published certificate of analysis (purity and identity), dated 2026-07-24. View the COA →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research